Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

7:59 AM ET Form 4
Insider Selling Radcom Ltd RDCM

Radcom Director Sami Totah Sells $66K of Stock

Sami Totah, Director, sold 6,000 shares of Radcom Ltd at $11.00 a share, worth $66K in total on Nov 12, 2026. Shares held after the trade: 24,175 (-19.9%).

Value
$66K
Shares
6,000
Price
$11.00
Role
Director
Holding change
-19.9%
Trade date
Nov 12, 2026
7:59 AM ET 8-K
Leadership Change Walmart Inc. WMT

Walmart Leadership Change

Walmart Inc. has appointed Joseph E. Creed, the Chairman and CEO of Caterpillar Inc., to its Board of Directors, effective November 13, 2026. Mr. Creed will serve on the Audit and Strategic Planning and Finance Committees and will receive a prorated portion of the standard non-management director compensation, which includes a $230,000 annual stock award and a $115,000 annual retainer.

Counterparty
Joseph E. Creed
7:58 AM ET Form 4
Insider Selling Radcom Ltd RDCM

Radcom CTO Ram Amit Sells $33K of Stock

Ram Amit, CTO, sold 3,000 shares of Radcom Ltd at $10.99 a share, worth $33K in total on Nov 13, 2026. Shares held after the trade: 75,813 (-3.8%).

Value
$33K
Shares
3,000
Price
$10.99
Role
CTO
Holding change
-3.8%
Trade date
Nov 13, 2026
7:56 AM ET 10-Q
Financial Results LanzaTech Global, Inc. LNZA

LanzaTech Global Q3 2026 Results: Net Loss of $178M

LanzaTech Global, Inc. reported total revenues of $30.5 million for the nine months ended September 30, 2026, compared to $27.8 million in the prior year period. The company significantly reduced its research and development expenses from $41.7 million to $10.8 million year-over-year, contributing to a narrowed accumulated deficit. However, the filing includes a cautionary note regarding the company's ability to continue as a going concern and its need for additional financing.

Key figure
Net loss $178M
7:56 AM ET 8-K
Financial Results Galectin Therapeutics Inc GALT

Galectin Therapeutics Financial Results

Galectin Therapeutics reported financial results for the quarter ended September 30, 2026, and provided a business update on its Phase 3 clinical trial protocol for belapectin in MASH cirrhosis. The company reached alignment with the FDA on the Phase 3 trial design and presented positive new analyses from its NAVIGATE trial at the AASLD Annual Meeting.

Term
3 months

“New analyses were presented at AASLD, marking the fourth consecutive major liver conference where Galectin data was included in an oral presentation. We were extremely pleased by the positive feedback received on the oral presentation as well as the two poster presentations and are excited that our data was included in the AASLD conference highlights and the portal hypertension debrief.”

Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics

“As previously disclosed, we submitted our registrational Phase 3 protocol to FDA in the third quarter after reaching alignment on primary elements of the planned Phase 3 trial design. Additional information is expected to be presented at the Annual Stockholders’ Meeting on December 3, 2026.”

Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics
7:54 AM ET 8-K
M&A Deal IX Acquisition Corp. IXAQF

IX Acquisition M&A Deal Update

IX Acquisition Corp. provided a status update regarding its pending business combination involving Parent and Merger Sub. The filing includes forward-looking statements concerning the anticipated initial enterprise value, post-closing equity value, and the expected timing for the consummation of the transaction.

7:53 AM ET 8-K
M&A Deal Ameris Bancorp ABCB

Ameris Bancorp M&A Deal with Bank of Central Florida Holding Company

Ameris Bancorp (ABCB) has entered into a definitive agreement to acquire Bank of Central Florida Holding Company (BOCF) in an all-stock merger transaction. BOCF shareholders will receive 0.6279 shares of Ameris common stock for each share held, representing an implied value of $51.80 per share. The deal expands Ameris's presence in the Lakeland and Tampa markets and is expected to close in the first quarter of 2027.

Counterparty
Bank of Central Florida Holding Company
7:53 AM ET 8-K
Financial Results LanzaTech Global, Inc. LNZA

LanzaTech Global Financial Results

LanzaTech Global reported Q3 2026 revenue of $9.5 million and a net loss of $178.0 million, which was primarily driven by a $166.4 million non-cash unrealized fair value loss on its investment in SGLT. The company highlighted significant cost reductions, with operating expenses down 35% year-over-year, and achieved the world's first ISCC EU certification for recycled carbon fuels from steel mill waste gases.

Term
Q3 2026

“Our third quarter results show continued improvement in our financial and operating performance, building on the progress we have made throughout 2026. The actions we took to reshape LanzaTech are now showing up in our results quarter after quarter; we have held quarterly operating expenses steady for multiple quarters, which tells us the lower cost base we built is durable and sustainable. Our cost structure is now reset for where we are headed operationally and strategically, and LanzaTech now has a much improved position upon which to advance its platform toward commercialization and long-term profitability.”

Dr. Jennifer Holmgren, CEO of LanzaTech

“We are building a business that can monetize waste carbon across multiple end markets rather than depend on a single route to market. This quarter, Hebei Shoulang, a commercial facility using LanzaTech technology, achieved the world’s first ISCC EU Recycled Carbon Fuel certification for ethanol made from steel mill waste gases. This creates a near-term pathway into European road and marine fuel markets, and we have begun commercial discussions with major energy and chemicals companies to convert certification into revenue.”

Dr. Jennifer Holmgren, CEO of LanzaTech
7:53 AM ET 8-K
M&A Deal Surgery Partners, Inc. SGRY

Surgery Partners M&A Deal with Bon Secours Mercy Health, Inc.

Surgery Partners announced a consent solicitation for its $1.225 billion 7.250% Senior Notes due 2032 to amend the indenture in connection with its pending merger with Spyglass Topco, LLC and Bon Secours Mercy Health. The amendments seek to designate the acquirers as 'Permitted Holders' to prevent the merger from triggering a 'Change of Control' repurchase obligation under the debt agreement.

Counterparty
Bon Secours Mercy Health, Inc.
7:51 AM ET 10-Q
Financial Results Galectin Therapeutics Inc GALT

Galectin Therapeutics Q3 2026 Results: Net Loss of $3.53M, Loss Narrows

Galectin Therapeutics reported a net loss of $17.7 million for the nine months ended September 30, 2026, an improvement from the $25.3 million loss in the prior year period. A significant balance sheet event occurred with the conversion of $105.2 million in debt into common stock, substantially reducing total liabilities and increasing the common shares outstanding to over 100 million.

Key figure
Net loss $3.53M
7:51 AM ET 10-K
Financial Results Tyson Foods, Inc. TSN

Tyson Foods FY 2026 Results: Net Income $453M

Tyson Foods reported 2026 sales of $56.4 billion, a 3.6% increase driven by higher average sales prices and an additional fiscal week. Despite sales growth, net income attributable to Tyson decreased slightly to $453 million, impacted by significant restructuring charges, legal contingency accruals, and continued operating losses in the Beef segment.

Key figure
Net income $453M
7:47 AM ET 8-K
Leadership Change Montauk Renewables, Inc. MNTK

Montauk Renewables Leadership Change

Kevin Van Asdalan informed Montauk Renewables of his intention to resign as Chief Financial Officer, effective December 9, 2026. The company stated the departure is not due to any conflict or disagreement and expects to identify an interim CFO during the transition period.

7:46 AM ET 8-K
Financial Results Montauk Renewables, Inc. MNTK

Montauk Renewables Financial Results

Montauk Renewables reported Q3 2026 revenues of $50.2 million, a 10.9% increase year-over-year, though net income fell 58.9% to $2.1 million. The company announced it has executed a non-binding term sheet to amend its credit facility to borrow additional debt and address liquidity concerns, avoiding a previously anticipated going concern qualification. Additionally, the company plans to invest $15.0 million in enhancements at its Turkey, North Carolina facility to address feedstock moisture and syngas temperature issues limiting commercial production.

Term
Q3 2026
7:45 AM ET 8-K
Financial Results Creative Realities, Inc. CREX

Creative Realities Financial Results

Creative Realities reported Q3 2026 revenue of $26.2 million, a significant increase from $10.5 million in the prior-year period, driven by the acquisition of Cineplex Digital Media and new contract wins. The company reported Adjusted EBITDA of $2.7 million and annualized recurring revenue (ARR) of $21.7 million. Management expects full-year 2026 revenue to exceed $100 million, supported by retail media deployments and stadium installations.

Term
Q3 2026

“We continue to set new records this year in terms of growth acceleration, business wins, and EBITDA expansion. We anticipate revenue exceeding $100 million in fiscal 2026, as the fourth quarter is expected to benefit from seasonal factors related to our retail media contracts as well as from the positive impact of recent awards and new customer installations.”

Rick Mills, Chief Executive Officer

“We focused on the balance sheet this quarter, using existing cash to pay down debt, provide increased financial flexibility, and reduce ongoing interest expense. Our talented staff and leadership successfully executed an operating strategy that is producing significant growth as we become a more nimble organization intent on achieving improved bottom line results and cash generation.”

Rick Mills, Chief Executive Officer
7:45 AM ET 8-K
Clinical Trial Data Cerenome, Inc. CNSY

Cerenome Clinical Trial Data

Cerenome reported interim data from its Phase 1 ReSPECT-LM study evaluating repeat dosing of REYOBIQ in patients with leptomeningeal metastases. The data showed no dose-limiting toxicities in the first 10 patients and indicated consistent radiation delivery across repeat administrations, with early disease control signals showing no progression in evaluable patients at the six-month landmark.

Counterparty
Society for Neuro-Oncology
7:44 AM ET 8-K
M&A Deal Mara Holdings, Inc. MARA

Mara Holdings Signs $1.5B M&A Deal with Long Ridge Energy & Power LLC

MARA Holdings subsidiary MARA USA Corporation has commenced a $185 million private offering of senior secured notes to fund its previously announced $1.5 billion acquisition of Long Ridge Energy & Power LLC. The acquisition includes 100% of the membership interests in the target, which is the parent of Long Ridge Energy LLC. Proceeds will also be used to repay existing indebtedness and cover transaction fees.

Value
$1.5B
Counterparty
Long Ridge Energy & Power LLC
7:44 AM ET 8-K
Financial Results Tyson Foods, Inc. TSN

Tyson Foods Financial Results

Tyson Foods reported fourth quarter and fiscal year 2026 results, with annual sales increasing 3.6% to $56.4 billion. While GAAP operating income remained flat at $1.1 billion, adjusted EPS for the full year declined 17% to $3.44, reflecting a challenging operating environment despite growth in Prepared Foods and resilience in the Chicken segment.

“Our performance in fiscal 2026 reflects the strength of our diversified multiprotein model and our dedication to our customers and consumers. We’ll build on those strengths through investment in our brands, innovation and operating capabilities, while remaining focused on the returns those investments can deliver alongside market conditions.”

Jeff Schomburger, President and CEO of Tyson Foods
7:36 AM ET 8-K
Financial Results Edible Garden AG Inc EDBL

Edible Garden AG Financial Results

Edible Garden reported third quarter 2026 financial results, featuring a 14% revenue increase to $3.2 million and a significant gross margin expansion to 23.9%. The company highlighted strong growth in cut herb sales and secured a major private-label RTD protein beverage award from a large grocery retailer. Management noted that these improvements were achieved during the company's seasonally slowest quarter.

Term
Q3 2026

“Our third-quarter results reflect meaningful progress in strengthening our business.”

Jim Kras, Chief Executive Officer of Edible Garden
7:35 AM ET 8-K
Financial Results Vida Global Inc. VIDA

Vida Global Financial Results

VIDA Global reported Q3 2026 financial results with revenue increasing 88% year-over-year to $0.33 million. The company highlighted the transition of its computer agents out of beta and the expansion of its go-to-market team and partnerships with ALLO Fiber and AVANT.

Term
Q3 2026

“In the third quarter, we believe we put the foundation in place to scale Vida’s AI workforce. Our computer agents came out of beta, so Vida’s AI employees now have the ability to do the work behind the conversation, not just the conversation. We built outcome-based billing, expanded our sales team, and signed partners including ALLO Fiber and AVANT.”

Lyle Pratt, Founder and CEO of Vida Global
7:31 AM ET Form 4
Insider Buying CorMedix Inc. CRMD

CorMedix CEO Joseph Todisco Buys $391K of Stock

Joseph Todisco, CEO, bought 80,000 shares of CorMedix Inc. at $4.89 a share, worth $391K in total on Nov 13, 2026. Shares held after the trade: 854,749 (+10.3%).

Value
$391K
Shares
80,000
Price
$4.89
Role
CEO
Holding change
+10.3%
Trade date
Nov 13, 2026
7:31 AM ET 10-Q
Financial Results Agape ATP Corp ATPC

Agape ATP Q3 2026 Results: Net Loss of $83.7K, Loss Narrows

Agape ATP Corp reported a significant decline in revenue to $40,079 for the nine months ended September 30, 2026, compared to $352,844 in the prior year. Despite the revenue drop, the net loss narrowed to $275,153 from $1,931,535, primarily due to a substantial $1.3 million foreign exchange gain and income from the disposal of discontinued operations.

Key figure
Net loss $83.7K
7:31 AM ET 10-Q
Financial Results ZW Data Action Technologies Inc. CNET

ZW Data Action Technologies Q3 2026 Results: Net Loss of $182K, Loss Widens

ZW Data Action Technologies Inc. reported total assets of $10.68 million as of September 30, 2026, an increase from $9.68 million at the end of 2025. The company continues to navigate regulatory risks associated with the Holding Foreign Companies Accountable Act (HFCAA) due to its auditor's location in Hong Kong.

Key figure
Net loss $182K
7:31 AM ET 10-Q
Financial Results MapLight Therapeutics, Inc. MPLT

MapLight Therapeutics Q3 2026 Results: Net Loss of $51.6M, Loss Widens

MapLight Therapeutics reported a significant increase in net loss to $172.5 million for the nine months ended September 30, 2026, compared to $81.6 million in the prior year, primarily driven by a doubling of research and development expenses. The company strengthened its balance sheet through a private placement in the third quarter of 2026, yielding $140.1 million in net proceeds.

Key figure
Net loss $51.6M
7:31 AM ET 10-Q
Financial Results CNS Pharmaceuticals, Inc. CNSP

CNS Pharmaceuticals Q3 2026 Results: Net Loss of $2.5M, Loss Narrows

CNS Pharmaceuticals reported a net loss of $10.0 million for the nine months ended September 30, 2026, while significantly strengthening its cash position to $17.2 million following a $22.5 million private placement in May 2026. The company is currently pivoting its corporate strategy toward acquiring new therapeutic assets and exploring out-licensing opportunities for its legacy glioblastoma programs.

Key figure
Net loss $2.5M
7:31 AM ET 8-K
Capital Raise Medicus Pharma Ltd. MDCX

Medicus Pharma Capital Raise of $3M

Medicus Pharma Ltd. entered into a securities purchase agreement for a registered direct offering of 97,973 common shares and 1,646,213 pre-funded warrants for gross proceeds of approximately $3.0 million. Additionally, the company executed a debt-for-equity exchange with Streeterville Capital, LLC, partitioning $10.5 million in principal from an existing secured promissory note into 105,000 non-convertible preferred shares to reduce its debt obligations.

Value
$3M
7:31 AM ET 10-Q
Financial Results Fitlife Brands, Inc. FTLF

Fitlife Brands Q3 2026 Results: Net Income $1.57M, Up 70.6% YoY

FitLife Brands reported a 39.5% increase in revenue for the nine months ended September 30, 2026, reaching $77.5 million compared to $55.5 million in the prior year. Net income for the nine-month period rose to $5.24 million, driven by organic growth and the impact of the Irwin acquisition, despite higher interest expenses and selling costs.

Key figure
Net income $1.57M · +70.6% YoY
7:31 AM ET 8-K
Financial Results Moleculin Biotech, Inc. MBRX

Moleculin Biotech Financial Results

Moleculin Biotech reported Q3 2026 financial results and announced the completion of treatment for all 90 patients in Part A of its pivotal Phase 2/3 MIRACLE trial for Annamycin in AML. The company remains on track for a comprehensive data readout in Q1 2027, which will inform dose selection for the planned initiation of Part B in the first half of 2027.

“We are approaching one of the most important milestones in Moleculin's development, and I believe our progress has positioned us to enter 2027 with meaningful momentum. Completing treatment of all 90 patients in Part A of our pivotal MIRACLE trial is a significant execution achievement.”

Walter Klemp, Chairman and Chief Executive Officer of Moleculin

“We have reported encouraging interim clinical findings, strengthened the scientific foundation supporting Annamycin's differentiated cardiac safety profile through independent, peer-reviewed analysis, and continued to execute against our pivotal development strategy.”

Walter Klemp, Chairman and Chief Executive Officer of Moleculin
7:28 AM ET 8-K
M&A Deal Macerich Co MAC

Macerich Signs $250M M&A Deal with Oakridge Mall

The Macerich Company announced the acquisition of Oakridge Mall, a 1.1 million square foot super-regional retail center in San Jose, California, for approximately $250 million. The acquisition is funded through the partial settlement of 11 million shares of common stock previously sold on a forward basis in June 2026 at an initial forward price of $23.12 per share.

Value
$250M
Counterparty
Oakridge Mall
7:22 AM ET 10-Q
Financial Results Prelude Therapeutics Inc PRLD

Prelude Therapeutics Q3 2026 Results: Net Loss of $12.5M, Loss Narrows

Prelude Therapeutics reported a net loss of $36.9 million for the nine months ended September 30, 2026, a significant improvement from the $83.0 million loss in the prior year period, driven by a decrease in R&D expenses and $15.9 million in recognized revenue. The company strengthened its balance sheet through a $90.0 million issuance of common stock and pre-funded warrants, ending the period with $142.4 million in total current assets.

Key figure
Net loss $12.5M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.